Updated on 29 August 2025
Conjugated drug development platform
About
Serilink is a company specializes in bioconjugation for conjugated drug development. We are a spin-off from chemistry department of HKU.
We are utilizing our in-house novel conjugation technology to develop various conjugated drug, with a focus on antibody-drug conjugate (ADC), peptide-drug conjugate (PDC) and radionuclide-drug conjugate (RDC).
We are seeking funding to support our pre-clinical studies for our PCC and also finding collaborators for co-development project.
Project Location
- China (Hong Kong)
Project Format
- Private Project
ESG (Environmental, Social, and Governance)
- No
Project Stage
- Project Planning
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Total Project Value
- 5,000,001 to 7,500,000 USD
Investment Capital Required
- 1,000,001 to 2,500,000 USD
Interested Format of Cooperation
- Joint Venture
- Open for Negotiation
- R&D Cooperation
Preferred Financing Model
- Open for negotiation
Previous Funding Stage
- Seed & Pre-Series
Main Service(s) Required
- Financial Services
- Professional Services
Financial Services
- Private Equity & Venture Capital
Professional Services
- Business Valuation
- Consultancy
- IP Related
Attached files
Organisation
Serilink Biotechnology Company Limited
Hong Kong, China (Hong Kong)
Similar opportunities
Project
- Yes
- IPO
- Bio-Tech
- Technology
- Hedge Funds
- Manufacturing
- Private Project
- R&D Cooperation
- Fund Management
- Wealth Management
- Financial Services
- Open for Negotiation
- Minority Shareholdings
- 50,000,001 USD or above
- Institutional Investment
- Feasibility Study Completed
- Private Equity & Venture Capital
灵鸽 刘
投资者关系副总监 at 东曜药业有限公司
苏州, China
Project
Organ-in-Cube: Next Generation Bionic Organ for Precision Medicine
- No
- Bio-Tech
- Operations
- Technology
- IP Related
- Consultancy
- R&D Cooperation
- Risk Management
- Health Technology
- Seed & Pre-Series
- Medical Technology
- Financial Services
- Business Valuation
- Financial Advisory
- Open for Negotiation
- Open for negotiation
- Professional Services
- 5,000,001 to 7,500,000 USD
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
- Public-Private Partnership Project
- Risk Management (Financial Services)
Jiang Liu
Research Assistant Professor at Oncoimmunostics Limited
Hong Kong, China (Hong Kong)
Project
- No
- Bio-Tech
- Technology
- Joint Venture
- R&D Cooperation
- Project Planning
- Health Technology
- Seed & Pre-Series
- Financial Services
- 500,000 USD or Below
- Open for Negotiation
- Open for negotiation
- Professional Services
- Requisition of Service
- 1,000,001 to 2,500,000 USD
- Public-Private Partnership Project
Daisy Tan
Business Development Manager at InnoHK Centre for Translational Stem Cell Biology
Hong Kong, China (Hong Kong)